Shorter venetoclax after AML remission
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing if a shorter course of venetoclax can still work well after you've already achieved remission with standard venetoclax-based treatment for AML. The goal is to reduce side effects while keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Acute Myeloid Leukemia (AML).
- You received your first treatment with either azacitidine plus venetoclax or decitabine plus venetoclax.
- You achieved remission (bone marrow blasts less than 5%) within 3 cycles of that treatment.
- Your blood counts have recovered on their own (no transfusions needed for 7 days) and you haven't used growth factor shots in the last 14 days.
- You are not eligible for or have declined a stem cell transplant, and you are not eligible for intensive chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests if a shorter course of venetoclax, based on early bone marrow results, works as well as the standard longer course. It is for older adults or younger patients with health issues that make standard intensive chemo too risky.
This trial tests whether it's safe to stop the combination of venetoclax and azacitidine (VEN-AZA) in people with AML whose cancer has completely disappeared and who have no detectable leukemia cells left. If you've been on VEN-AZA for about a year and are in deep remission, this study may help you avoid unnecessary treatment.
This trial compares a shorter course (7 days) of the targeted drug venetoclax with the standard longer course, both given along with the chemotherapy drug azacitidine. It is for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
Hear when a new Acute Myeloid Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.